U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C17H18N6.H3O4P
Molecular Weight 404.3602
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of RUXOLITINIB PHOSPHATE

SMILES

OP(O)(O)=O.N#CC[C@H](C1CCCC1)N2C=C(C=N2)C3=C4C=CNC4=NC=N3

InChI

InChIKey=JFMWPOCYMYGEDM-XFULWGLBSA-N
InChI=1S/C17H18N6.H3O4P/c18-7-5-15(12-3-1-2-4-12)23-10-13(9-22-23)16-14-6-8-19-17(14)21-11-20-16;1-5(2,3)4/h6,8-12,15H,1-5H2,(H,19,20,21);(H3,1,2,3,4)/t15-;/m1./s1

HIDE SMILES / InChI
Molecular Formula C17H18N6
Molecular Weight 306.365
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED
Molecular Formula H3O4P
Molecular Weight 97.9952
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Approval Year

Unknown
86413
Substance Class Chemical
Created
by admin
on Fri Dec 15 18:11:51 UTC 2023
Edited
by admin
on Fri Dec 15 18:11:51 UTC 2023
Record UNII
436LRU32H5
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
RUXOLITINIB PHOSPHATE
MI   ORANGE BOOK   USAN   WHO-DD  
USAN  
Official Name English
1H-PYRAZOLE-1-PROPANENITRILE,.BETA.-CYCLOPENTYL-4-(7H-PYRROLO(2,3-D)PYRIMIDIN-4-YL)-,(.BETA.R)-,PHOSPHATE (1:1)
Common Name English
INCB-018424 PHOSPHATE
Code English
RUXOLITINIB (AS PHOSPHATE) [EMA EPAR]
EMA EPAR  
Common Name English
RUXOLITINIB PHOSPHATE [MI]
Common Name English
JAKAVI
Brand Name English
RUXOLITINIB PHOSPHATE [ORANGE BOOK]
Common Name English
RUXOLITINIB MONOPHOSPHATE
Common Name English
Ruxolitinib phosphate [WHO-DD]
Common Name English
INCB018424 PHOSPHATE
Code English
(3R)-3-Cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile phosphate (1:1)
Systematic Name English
JAKAFI
Brand Name English
RUXOLITINIB (AS PHOSPHATE)
Common Name English
INCB-18424 PHOSPHATE
Code English
OPZELURA
Brand Name English
RUXOLITINIB PHOSPHATE [USAN]
Common Name English
INCB-018424 SALT
Code English
RUXOLITINIB PHOSPHATE [JAN]
Common Name English
Classification Tree Code System Code
FDA ORPHAN DRUG 265308
Created by admin on Fri Dec 15 18:11:51 UTC 2023 , Edited by admin on Fri Dec 15 18:11:51 UTC 2023
NCI_THESAURUS C1967
Created by admin on Fri Dec 15 18:11:51 UTC 2023 , Edited by admin on Fri Dec 15 18:11:51 UTC 2023
FDA ORPHAN DRUG 302510
Created by admin on Fri Dec 15 18:11:51 UTC 2023 , Edited by admin on Fri Dec 15 18:11:51 UTC 2023
NCI_THESAURUS C129825
Created by admin on Fri Dec 15 18:11:51 UTC 2023 , Edited by admin on Fri Dec 15 18:11:51 UTC 2023
EMA ASSESSMENT REPORTS JAKAVI (AUTHORIZED: MYELOPROLIFERATIVE DISORDERS)
Created by admin on Fri Dec 15 18:11:51 UTC 2023 , Edited by admin on Fri Dec 15 18:11:51 UTC 2023
Code System Code Type Description
PUBCHEM
25127112
Created by admin on Fri Dec 15 18:11:51 UTC 2023 , Edited by admin on Fri Dec 15 18:11:51 UTC 2023
PRIMARY
NCI_THESAURUS
C97937
Created by admin on Fri Dec 15 18:11:51 UTC 2023 , Edited by admin on Fri Dec 15 18:11:51 UTC 2023
PRIMARY
RXCUI
1193325
Created by admin on Fri Dec 15 18:11:51 UTC 2023 , Edited by admin on Fri Dec 15 18:11:51 UTC 2023
PRIMARY RxNorm
DAILYMED
436LRU32H5
Created by admin on Fri Dec 15 18:11:51 UTC 2023 , Edited by admin on Fri Dec 15 18:11:51 UTC 2023
PRIMARY
EU-Orphan Drug
EU/3/08/572(WITHDRAWN)
Created by admin on Fri Dec 15 18:11:51 UTC 2023 , Edited by admin on Fri Dec 15 18:11:51 UTC 2023
PRIMARY Please note that this product was withdrawn from the Community Register of designated orphan medicinal products in February 2015 on request of the sponsor. On 7 November 2008, orphan designation (EU/3/08/572) was granted by the European Commission to Incyte Corporation Ltd, United Kingdom, for (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile phosphate for the treatment of chronic idiopathic myelofibrosis. The sponsorship was transferred to Novartis Europharm Limited, United Kingdom, in September 2010. (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile phosphate in treatment of chronic idiopathic myelofibrosis has been authorised in the EU as Jakavi since 23 August 2012.
EVMPD
SUB32897
Created by admin on Fri Dec 15 18:11:51 UTC 2023 , Edited by admin on Fri Dec 15 18:11:51 UTC 2023
PRIMARY
DRUG BANK
DBSALT000156
Created by admin on Fri Dec 15 18:11:51 UTC 2023 , Edited by admin on Fri Dec 15 18:11:51 UTC 2023
PRIMARY
EPA CompTox
DTXSID00911086
Created by admin on Fri Dec 15 18:11:51 UTC 2023 , Edited by admin on Fri Dec 15 18:11:51 UTC 2023
PRIMARY
SMS_ID
100000126279
Created by admin on Fri Dec 15 18:11:51 UTC 2023 , Edited by admin on Fri Dec 15 18:11:51 UTC 2023
PRIMARY
FDA UNII
436LRU32H5
Created by admin on Fri Dec 15 18:11:51 UTC 2023 , Edited by admin on Fri Dec 15 18:11:51 UTC 2023
PRIMARY
USAN
UU-161
Created by admin on Fri Dec 15 18:11:51 UTC 2023 , Edited by admin on Fri Dec 15 18:11:51 UTC 2023
PRIMARY
MERCK INDEX
m9710
Created by admin on Fri Dec 15 18:11:51 UTC 2023 , Edited by admin on Fri Dec 15 18:11:51 UTC 2023
PRIMARY Merck Index
ChEMBL
CHEMBL1789941
Created by admin on Fri Dec 15 18:11:51 UTC 2023 , Edited by admin on Fri Dec 15 18:11:51 UTC 2023
PRIMARY
CHEBI
66917
Created by admin on Fri Dec 15 18:11:51 UTC 2023 , Edited by admin on Fri Dec 15 18:11:51 UTC 2023
PRIMARY
EU-Orphan Drug
EU/3/09/620(WITHDRAWN)
Created by admin on Fri Dec 15 18:11:51 UTC 2023 , Edited by admin on Fri Dec 15 18:11:51 UTC 2023
PRIMARY Please note that this product was withdrawn from the Community Register of designated Orphan Medicinal Products in February 2015 on request of the sponsor. On 3 April 2009, orphan designation (EU/3/09/620) was granted by the European Commission to Incyte Corporation Ltd, United Kingdom, for (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile phosphate for the treatment of myelofibrosis secondary to polycythaemia vera or essential thrombocythaemia. The sponsorship was transferred to Novartis Europharm Limited, United Kingdom, in September 2010. R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile phosphate in treatment of myelofibrosis secondary to polycythaemia vera or essential thrombocythaemia has been authorised in the EU as Jakavi since 23 August 2012.
CAS
1092939-17-7
Created by admin on Fri Dec 15 18:11:51 UTC 2023 , Edited by admin on Fri Dec 15 18:11:51 UTC 2023
PRIMARY
Related Record Type Details
Structure of RUXOLITINIB
PARENT -> SALT/SOLVATE
Related Record Type Details
Structure of RUXOLITINIB
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966